An update on glutamatergic system in suicidal depression and on the role of esketamine

Current Topics in Medicinal Chemistry

Volumn 20, Issue 7, 2020, Pages 554-584

  De Berardis, Domenico ^a,b,c   Tomasetti, Carmine ^c,d,e   Pompili, Maurizio ^f   Serafini, Gianluca ^g   Vellante, Federica ^a   Fornaro, Michele ^c,d   Valchera, Alessandro ^c,h   Perna, Giampaolo ^i,j,k   Volpe, Umberto ^l   Martinotti, Giovanni ^a   Fraticelli, Silvia ^a   Di Giannantonio, Massimo ^a   Kim, Yong Ku ^m   Orsolini, Laura ^c,n,o  

^a University of "G D Annunzio"   (Italy)

^b Hospital G Mazzini   (Italy)

^c Polyedra   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e Hospital SS Annunziata   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h Hermanas Hospitalarias   (Italy)

ⁱ Department of Clinical Neurosciences   (Italy)

^j MAASTRICHT UNIVERSITY   (Netherlands)

^k MIAMI UNIVERSITY   (United States)

^l UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^m Korea University College of Medicine   (South Korea)

ⁿ UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^o Villa Jolanda Hospital   (Italy)

more..

Author keywords

Depression; Esketamine; Glutamate; Glutamatergic system; Ketamine; MDD; Suicide; Treatment resistant depression

Indexed keywords

4 AMINOBUTYRIC ACID; ELONGATION FACTOR 2; ESKETAMINE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; ANTIDEPRESSANT AGENT; GLUTAMIC ACID;

ANTIDEPRESSANT ACTIVITY; BIPOLAR DISORDER; DATA BASE; DRUG BIOAVAILABILITY; DRUG DOSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DSM-IV-TR; FOOD AND DRUG ADMINISTRATION; GLUTAMATERGIC SYSTEM; HIGH RISK PATIENT; HUMAN; MAJOR DEPRESSION; NEUROMODULATION; NEUROTRANSMISSION; REVIEW; SINGLE DRUG DOSE; SUICIDAL BEHAVIOR; SUICIDAL DEPRESSION; SUICIDAL IDEATION; SUICIDE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT RESISTANT DEPRESSION; CLINICAL TRIAL (TOPIC); DEPRESSION; DRUG EFFECT; DRUG FORMULATION; FACTUAL DATABASE; INTRANASAL DRUG ADMINISTRATION; METABOLISM; SYNAPTIC TRANSMISSION; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, INTRANASAL; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DRUG COMPOUNDING; GLUTAMIC ACID; HUMANS; KETAMINE; RECEPTORS, N-METHYL-D-ASPARTATE; SUICIDE; SYNAPTIC TRANSMISSION; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85082860849     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026620666200131100316     Document Type: Review

References (141)

1. Hasin, D.S.; Sarvet, A.L.; Meyers, J.L.; Saha, T.D.; Ruan, W.J.; Stohl, M.; Grant, B.F. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry, 2018, 75(4), 336-346. http://dx.doi.org/10.1001/jamapsychiatry.2017.4602 PMID:29450462
2. WHO. Suicide; World Health Organization: Geneva, Switzerland, 2018. (Accessed 30 September 2019)
3. Liu, Q.; He, H.; Yang, J.; Feng, X.; Zhao, F.; Lyu, J. Changes in the global burden of depression from 1990 to 2017: Findings from the global burden of disease study. J. Psychiatr. Res., 2019, pii: S0022-3956(19), 30738-1.
4. Patten, S.B.; Williams, J.V.; Lavorato, D.H.; Wang, J.L.; McDonald, K.; Bulloch, A.G. Descriptive epidemiology of major depressive disorder in Canada in 2012. Can. J. Psychiatry, 2015, 60(1), 23-30. http://dx.doi.org/10.1177/070674371506000106 PMID: 25886546
5. Yang, L.; Zhao, Y.; Wang, Y.; Liu, L.; Zhang, X.; Li, B.; Cui, R. The effects of psychological stress on depression. Curr. Neuropharmacol., 2015, 13(4), 494-504. http://dx.doi.org/10.2174/1570159X1304150831150507 PMID:26412069
6. Chang, B.; Choi, Y.; Jeon, M.; Lee, J.; Han, K.M.; Kim, A.; Ham, B.J.; Kang, J. ARPNet: antidepressant response prediction network for major depressive Disorder. Genes (Basel), 2019, 10(11)E907 http://dx.doi.org/10.3390/genes10110907 PMID: 31703457
7. Canuso, C.M.; Singh, J.B.; Fedgchin, M.; Alphs, L.; Lane, R.; Lim, P.; Pinter, C.; Hough, D.; Sanacora, G.; Manji, H.; Drevets, W.C. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebocontrolled study. Am. J. Psychiatry, 2018, 175(7), 620-630. http://dx.doi.org/10.1176/appi.ajp.2018.17060720 PMID: 29656663
8. WHO. Depression and other common mental disorders: global health estimates, 2017. Available from:https://apps.who.int/iris/bitstream/handle/10665/254610/WHOMSD-MER-2017.2eng.pdf;jsessionid=073A899990718FDDE11F70671E1D49 D1?sequence=1.
9. De Berardis, D.; Fornaro, M.; Valchera, A.; Cavuto, M.; Perna, G.; Di Nicola, M.; Serafini, G.; Carano, A.; Pompili, M.; Vellante, F.; Orsolini, L.; Fiengo, A.; Ventriglio, A.; Yong-Ku, K.; Martinotti, G.; Di Giannantonio, M.; Tomasetti, C. Eradicating suicide at its roots: preclinical bases and clinical evidence of the efficacy of ketamine in the treatment of suicidal behaviors. Int. J. Mol. Sci., 2018, 19(10), E2888. http://dx.doi.org/10.3390/ijms19102888 PMID: 30249029
10. Molero, P.; Ramos-Quiroga, J.A.; Martin-Santos, R.; Calvo-Sánchez, E.; Gutiérrez-Rojas, L.; Meana, J.J. Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review. cns drugs, 2018, 32(5), 411-420. http://dx.doi.org/10.1007/s40263-018-0519-3 PMID: 29736744
11. Garay, R.P.; Zarate, C.A., Jr; Charpeaud, T.; Citrome, L.; Correll, C.U.; Hameg, A.; Llorca, P.M. Investigational drugs in recent clinical trials for treatment-resistant depression. Expert Rev. Neurother., 2017, 17(6), 593-609. http://dx.doi.org/10.1080/14737175.2017.1283217 PMID:28092469
12. Thase, M.E. New medications for treatment-resistant depression: a brief review of recent developments. CNS Spectr., 2017, 22(S1), 39-48. http://dx.doi.org/10.1017/S1092852917000876 PMID: 29350129
13. Pochwat, B.; Nowak, G.; Szewczyk, B. An update on NMDA antagonists in depression. Expert Rev. Neurother., 2019, 19(11), 1055-1067. http://dx.doi.org/10.1080/14737175.2019.1643237 PMID:31328587
14. Ragguett, R.M.; Tamura, J.K.; McIntyre, R.S. Keeping up with the clinical advances: depression. CNS Spectr., 2019, 24(S1), 25-37. http://dx.doi.org/10.1017/S1092852919001159 PMID: 31248466
15. Swainson, J.; Thomas, R.K.; Archer, S.; Chrenek, C.; MacKay, M.A.; Baker, G.; Dursun, S.; Klassen, L.J.; Chokka, P.; Demas, M.L. Esketamine for treatment resistant depression. Expert Rev. Neurother., 2019, 19(10), 899-911. http://dx.doi.org/10.1080/14737175.2019.1640604 PMID:31282772
16. Tomasetti, C.; Montemitro, C.; Fiengo, A.L.C.; Santone, C.; Orsolini, L.; Valchera, A.; Carano, A.; Pompili, M.; Serafini, G.; Perna, G.; Vellante, F.; Martinotti, G.; Giannantonio, M.D.; Kim, Y.K.; Nicola, M.D.; Bellomo, A.; Ventriglio, A.; Fornaro, M.; Berardis, D.D. Novel pathways in the treatment of major depression: focus on the glutamatergic system. Curr. Pharm. Des., 2019, 25(4), 381-387. http://dx.doi.org/10.2174/1381612825666190312102444 PMID:30864501
17. Smith, D.J.; Azzaro, A.J.; Zaldivar, S.B.; Palmer, S.; Lee, H.S. Properties of the optical isomers and metabolites of ketamine on the high affinity transport and catabolism of monoamines. Neuropharmacology, 1981, 20(4), 391-396. http://dx.doi.org/10.1016/0028-3908(81)90015-0 PMID: 7290352
18. Smith, D.J.; Bouchal, R.L.; deSanctis, C.A.; Monroe, P.J.; Amedro, J.B.; Perrotti, J.M.; Crisp, T. Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro. Neuropharmacology, 1987, 26(9), 1253-1260. http://dx.doi.org/10.1016/0028-3908(87)90084-0 PMID: 2823161
19. Hashimoto, K. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective. Psychiatry Clin. Neurosci., 2019, 73(10), 613-627. http://dx.doi.org/10.1111/pcn.12902 PMID: 31215725
20. Ritter, P.; Findeis, H.; Bauer, M. Ketamine in the treatment of depressive episodes. Pharmacopsychiatry, 2019. [Epub ahead of print] http://dx.doi.org/10.1055/a-0991-0582 PMID: 31434140
21. Covvey, J.R.; Crawford, A.N.; Lowe, D.K. Intravenous ketamine for treatment-resistant major depressive disorder. Ann. Pharmacother., 2012, 46(1), 117-123. [published online December 20, 2011]. http://dx.doi.org/10.1345/aph.1Q371 PMID: 22190250
22. Malhi, G.S.; Byrow, Y.; Cassidy, F.; Cipriani, A.; Demyttenaere, K.; Frye, M.A.; Gitlin, M.; Kennedy, S.H.; Ketter, T.A.; Lam, R.W.; McShane, R.; Mitchell, A.J.; Ostacher, M.J.; Rizvi, S.J.; Thase, M.E.; Tohen, M. Ketamine: stimulating antidepressant treatment? BJPsych Open, 2016, 2(3), e5-e9. http://dx.doi.org/10.1192/bjpo.bp.116.002923 PMID: 27703782
23. Berman, R.M.; Cappiello, A.; Anand, A.; Oren, D.A.; Heninger, G.R.; Charney, D.S.; Krystal, J.H. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry, 2000, 47(4), 351-354. http://dx.doi.org/10.1016/S0006-3223(99)00230-9 PMID:10686270
24. Wilkinson, S.T.; Sanacora, G. A new generation of antidepressants:an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems. Drug Discov. Today, 2019, 24(2), 606-615. http://dx.doi.org/10.1016/j.drudis.2018.11.007 PMID: 30447328
25. Bahr, R.; Lopez, A.; Rey, J.A. Intranasal esketamine (spravatotm) for use in treatment-resistant depression in conjunction with an oral antidepressant. P&T, 2019, 44(6), 340-375. PMID: 31160868
26. Kudoh, A.; Takahira, Y.; Katagai, H.; Takazawa, T. Small-dose ketamine improves the postoperative state of depressed patients. Anesth. Analg., 2002, 95(1), 114-118. http://dx.doi.org/10.1097/00000539-200207000-00020 PMID:12088953
27. Zarate, C.A., Jr; Brutsche, N.E.; Ibrahim, L.; Franco-Chaves, J.; Diazgranados, N.; Cravchik, A.; Selter, J.; Marquardt, C.A.; Liberty, V.; Luckenbaugh, D.A. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol. Psychiatry, 2012, 71(11), 939-946. http://dx.doi.org/10.1016/j.biopsych.2011.12.010 PMID: 22297150
28. Price, R.B.; Iosifescu, D.V.; Murrough, J.W.; Chang, L.C.; Al Jurdi, R.K.; Iqbal, S.Z.; Soleimani, L.; Charney, D.S.; Foulkes, A.L.; Mathew, S.J. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress. Anxiety, 2014, 31(4), 335-343. http://dx.doi.org/10.1002/da.22253 PMID: 24668760
29. Murrough, J.W.; Soleimani, L.; DeWilde, K.E.; Collins, K.A.; Lapidus, K.A.; Iacoviello, B.M.; Lener, M.; Kautz, M.; Kim, J.; Stern, J.B.; Price, R.B.; Perez, A.M.; Brallier, J.W.; Rodriguez, G.J.; Goodman, W.K.; Iosifescu, D.V.; Charney, D.S. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol. Med., 2015, 45(16), 3571-3580. http://dx.doi.org/10.1017/S0033291715001506 PMID: 26266877
30. Burger, J.; Capobianco, M.; Lovern, R.; Boche, B.; Ross, E.; Darracq, M.A.; McLay, R. A Double-blinded, randomized, placebocontrolled sub-dissociative dose ketamine pilot study in the treatment of acute depression and suicidality in a military emergency department setting. Mil. Med., 2016, 181(10), 1195-1199. http://dx.doi.org/10.7205/MILMED-D-15-00431 PMID: 27753551
31. Hu, Y.D.; Xiang, Y.T.; Fang, J.X.; Zu, S.; Sha, S.; Shi, H.; Ungvari, G.S.; Correll, C.U.; Chiu, H.F.; Xue, Y.; Tian, T.F.; Wu, A.S.; Ma, X.; Wang, G. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Psychol. Med., 2016, 46(3), 623-635. http://dx.doi.org/10.1017/S0033291715002159 PMID: 26478208
32. Grunebaum, M.F.; Ellis, S.P.; Keilp, J.G.; Moitra, V.K.; Cooper, T.B.; Marver, J.E.; Burke, A.K.; Milak, M.S.; Sublette, M.E.; Oquendo, M.A.; Mann, J.J. Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolam-controlled randomized clinical trial. Bipolar Disord., 2017, 19(3), 176-183. http://dx.doi.org/10.1111/bdi.12487 PMID: 28452409
33. Fan, W.; Yang, H.; Sun, Y.; Zhang, J.; Li, G.; Zheng, Y.; Liu, Y. Ketamine rapidly relieves acute suicidal ideation in cancer patients:a randomized controlled clinical trial. Oncotarget, 2017, 8(2), 2356-2360. http://dx.doi.org/10.18632/oncotarget.13743 PMID: 27926528
34. Grunebaum, M.F.; Galfalvy, H.C.; Choo, T.H.; Keilp, J.G.; Moitra, V.K.; Parris, M.S.; Marver, J.E.; Burke, A.K.; Milak, M.S.; Sublette, M.E.; Oquendo, M.A.; Mann, J.J. Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolamcontrolled randomized clinical trial. Am. J. Psychiatry, 2018, 175(4), 327-335. http://dx.doi.org/10.1176/appi.ajp.2017.17060647 PMID: 29202655
35. Newport, D.J.; Carpenter, L.L.; McDonald, W.M.; Potash, J.B.; Tohen, M.; Nemeroff, C.B. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am. J. Psychiatry, 2015, 172(10), 950-966. http://dx.doi.org/10.1176/appi.ajp.2015.15040465 PMID: 26423481
36. Andrade, C. Ketamine for depression, 3: does chirality matter? J. Clin. Psychiatry, 2017, 78(6), e674-e677. http://dx.doi.org/10.4088/JCP.17f11681 PMID: 28682536
37. Autry, A.E.; Adachi, M.; Nosyreva, E.; Na, E.S.; Los, M.F.; Cheng, P.F.; Kavalali, E.T.; Monteggia, L.M. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature, 2011, 475(7354), 91-95. http://dx.doi.org/10.1038/nature10130 PMID: 21677641
38. Marsden, W.N. Synaptic plasticity in depression: molecular, cellular and functional correlates. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2013, 43, 168-184. http://dx.doi.org/10.1016/j.pnpbp.2012.12.012 PMID: 23268191
39. Ignácio, Z.M.; Réus, G.Z.; Arent, C.O.; Abelaira, H.M.; Pitcher, M.R.; Quevedo, J. New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs. Br. J. Clin. Pharmacol., 2016, 82(5), 1280-1290. http://dx.doi.org/10.1111/bcp.12845 PMID: 26613210
40. Sattar, Y.; Wilson, J.; Khan, A.M.; Adnan, M.; Azzopardi Larios, D.; Shrestha, S.; Rahman, Q.; Mansuri, Z.; Hassan, A.; Patel, N.B.; Tariq, N.; Latchana, S.; Lopez Pantoja, S.C.; Vargas, S.; Shaikh, N.A.; Syed, F.; Mittal, D.; Rumesa, F. A Review of the Mechanism of Antagonism of N-methyl-D-aspartate Receptor by Ketamine in Treatment-resistant Depression. Cureus, 2018, 10(5), e2652. http://dx.doi.org/10.7759/cureus.2652 PMID: 30034974
41. Spravato. SpravatoTM (esketamine) prescribing information. Janssen Pharmaceuticals, Inc: Titusville, New Jersey, 2019.
42. Johnson & Johnson. Esketamine Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Major Depressive Disorder with Imminent Risk for Suicide. 2019. Avail https://www.fda.gov/NewsEvents/Newsroom/PressAnnounce ments/ucm632761.htm
43. Food and Drug Administration (FDA). FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic [news release]. Johnson & Johnson Media Center: Silver Spring, Maryland, March 5, 2019. Available at:https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm632761.htm [Accessed September 30, 2019].
44. Kaufman, M.B. Pharmaceutical Approval Update. P&T, 2019, 44(5), 251-254. PMID: 31080332
45. Kraus, C.; Wasserman, D.; Henter, I.D.; Acevedo-Diaz, E.; Kadriu, B.; Zarate, C.A., Jr. The influence of ketamine on drug discovery in depression. Drug Discov. Today, 2019, pii: S1359-6446(19), 30283-1. http://dx.doi.org/10.1016/j.drudis.2019.07.007
46. Niciu, M.J.; Henter, I.D.; Luckenbaugh, D.A.; Zarate, C.A.; Charney, D.S. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds., 2014. Available from http://www.annualreviews.org/doi/10.1146/annurev-pharmtox-011613-135950 http://dx.doi.org/10.1146/annurev-pharmtox-011613-135950
47. Fanta, S.; Kinnunen, M.; Backman, J.T.; Kalso, E. Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing. Euro. J. Clin. Pharm., 2015, 71(4), 441-447. http://dx.doi.org/10.1007/s00228-015-1826-y
48. Peltoniemi, M.A.; Hagelberg, N.M.; Olkkola, K.T.; Saari, T.I. Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin. Pharmacokinet., 2016, 55(9), 1059-1077.http://link.springer.com/10.1007/s40262-016-0383-6http://dx.doi.org/10.1007/s40262-016-0383-6 PMID: 27028535
49. Oye, I.; Paulsen, O.; Maurset, A. Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J. Pharmacol. Exp. Ther., 1992, 260(3), 1209-1213. PMID: 1312163
50. Kapur, S.; Seeman, P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Mol. Psychiatry, 2002, 7(8), 837-844. http://dx.doi.org/10.1038/sj.mp.4001093 PMID: 12232776
51. Lang, E.; Mallien, A.S.; Vasilescu, A.N.; Hefter, D.; Luoni, A.; Riva, M.A.; Borgwardt, S.; Sprengel, R.; Lang, U.E.; Gass, P.; Inta, D. Molecular and cellular dissection of NMDA receptor subtypes as antidepressant targets. Neurosci. Biobehav. Rev., 2018, 84, 352-358. http://dx.doi.org/10.1016/j.neubiorev.2017.08.012 PMID: 28843752
52. Li, L.; Vlisides, P.E. Ketamine: 50 years of modulating the mind. Front. Hum. Neurosci., 2016, 10, 612. http://journal.frontiersin.org/article/10.3389/fnhum.2016.00612/fullhttp://dx.doi.org/10.3389/fnhum.2016.00612 PMID: 27965560
53. Muller, J.; Pentyala, S.; Dilger, J.; Pentyala, S. Ketamine enantiomers in the rapid and sustained antidepressant effects. Ther. Adv. Psychopharmacol., 2016, 6(3), 185-192. http://journals.sagepub.com/doi/10.1177/2045125316631267 [Internet]. http://dx.doi.org/10.1177/2045125316631267 PMID: 27354907
54. Lener, M.S.; Kadriu, B.; Zarate, C.A., Jr. Ketamine and beyond:investigations into the potential of glutamatergic agents to treat depression. Drugs, 2017, 77(4), 381-401. http://link.springer.com/10.1007/s40265-017-0702-8 [Internet]. http://dx.doi.org/10.1007/s40265-017-0702-8 PMID: 28194724
55. Thomas, R.; Cetin, M.; Baker, G.B.; Dursun, S.M. Comment on FDA’s breakthrough therapy designation of intranasal esketamine for the treatment of major depressive disorder with imminent risk of suicide. Klinik Psikofarmakol. Bülteni, 2016, 26(4), 329-331. http://dx.doi.org/10.5455/bcp.20161027122045
56. Quintana, D.S.; Steen, N.E.; Andreassen, O.A. The promise of intranasal esketamine as a novel and effective antidepressant. JAMA Psychiatry, 2018, 75(2), 123-124. http://dx.doi.org/10.1001/jamapsychiatry.2017.3738 PMID:29282452
57. Turecki, G.; Ota, V.K.; Belangero, S.I.; Jackowski, A.; Kaufman, J. Early life adversity, genomic plasticity, and psychopathology. Lancet Psychiatry, 2014, 1(6), 461-466. http://dx.doi.org/10.1016/S2215-0366(14)00022-4 PMID:26361201
58. Oquendo, M.A.; Sullivan, G.M.; Sudol, K.; Baca-Garcia, E.; Stanley, B.H.; Sublette, M.E.; Mann, J.J. Toward a biosignature for suicide. Am. J. Psychiatry, 2014, 171(12), 1259-1277. http://dx.doi.org/10.1176/appi.ajp.2014.14020194 PMID: 25263730
59. Gao, S-F.; Bao, A-M. Corticotropin-releasing hormone, glutamate, and γ-aminobutyric acid in depression. Neuroscientist, 2011, 17(1), 124-144. http://dx.doi.org/10.1177/1073858410361780 PMID: 20236945
60. Ghosal, S.; Hare, B.; Duman, R.S. Prefrontal cortex gabaergic deficits and circuit dysfunction in the pathophysiology and treatment of chronic stress and depression. Curr. Opin. Behav. Sci., 2017, 14, 1-8. http://dx.doi.org/10.1016/j.cobeha.2016.09.012 PMID: 27812532
61. Chopin, E.; Kerkhof, A.; Theories, E.A-S.B. 2004. Available from books.google.com.
62. Joiner, T. E. Jr.; Silva, C. Why people die by suicide: Further development and tests of the interpersonal-psychological theory of suicidal behavior. In Meaning, mortality, and choice: The social psychology of existential concerns. P. R. Shaver & M. Mikulincer eds., American Psychological Association: Washington, p. 325-336.
63. Wenzel, A.; Brown, G.K.; Beck, A.T. Cognitive Therapy for Suicidal Patients: Scientific and Clinical Applications; American Psychological Association: Washington, 2009. http://dx.doi.org/10.1037/11862-000
64. Richard-Devantoy, S.; Turecki, G.; Jollant, F. Neurobiology of elderly suicide. Arch. Suicide Res., 2016, 20(3), 291-313. http://dx.doi.org/10.1080/13811118.2015.1048397 PMID:26743828
65. Anand, A.; Li, Y.; Wang, Y.; Wu, J.; Gao, S.; Bukhari, L.; Mathews, V.P.; Kalnin, A.; Lowe, M.J. Activity and connectivity of brain mood regulating circuit in depression: a functional magnetic resonance study. Biol. Psychiatry, 2005, 57(10), 1079-1088. http://dx.doi.org/10.1016/j.biopsych.2005.02.021 PMID: 15866546
66. Koenigs, M.; Grafman, J. The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex. Behav. Brain Res., 2009, 201(2), 239-243. http://dx.doi.org/10.1016/j.bbr.2009.03.004 PMID: 19428640
67. Moghaddam, B. Stress preferentially increases extraneuronal levels of excitatory amino acids in the prefrontal cortex: comparison to hippocampus and basal ganglia. J. Neurochem., 1993, 60(5), 1650-1657. http://dx.doi.org/10.1111/j.1471-4159.1993.tb13387.x PMID:8097232
68. Yuen, E.Y.; Liu, W.; Karatsoreos, I.N.; Feng, J.; McEwen, B.S.; Yan, Z. Acute stress enhances glutamatergic transmission in prefrontal cortex and facilitates working memory. Proc. Natl. Acad. Sci. USA, 2009, 106(33), 14075-14079. http://dx.doi.org/10.1073/pnas.0906791106 PMID: 19666502
69. Yuen, E.Y.; Wei, J.; Liu, W.; Zhong, P.; Li, X.; Yan, Z. Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex. Neuron, 2012, 73(5), 962-977. http://dx.doi.org/10.1016/j.neuron.2011.12.033 PMID: 22405206
70. Dalton, G.L.; Ma, L.M.; Phillips, A.G.; Floresco, S.B. Blockade of NMDA GluN2B receptors selectively impairs behavioral flexibility but not initial discrimination learning. Psychopharmacology (Berl.), 2011, 216(4), 525-535. http://dx.doi.org/10.1007/s00213-011-2246-z PMID: 21384103
71. Jett, J.D.; Bulin, S.E.; Hatherall, L.C.; McCartney, C.M.; Morilak, D.A. Deficits in cognitive flexibility induced by chronic unpredictable stress are associated with impaired glutamate neurotransmission in the rat medial prefrontal cortex. Neuroscience, 2017, 346, 284-297. http://dx.doi.org/10.1016/j.neuroscience.2017.01.017 PMID:28131625
72. Zhao, J.; Verwer, R.W.H.; Gao, S-F.; Qi, X-R.; Lucassen, P.J.; Kessels, H.W.; Swaab, D.F. Prefrontal alterations in GABAergic and glutamatergic gene expression in relation to depression and suicide. J. Psychiatr. Res., 2018, 102, 261-274. http://dx.doi.org/10.1016/j.jpsychires.2018.04.020 PMID:29753198
73. Bernstein, H-G.; Tausch, A.; Wagner, R.; Steiner, J.; Seeleke, P.; Walter, M.; Dobrowolny, H.; Bogerts, B. Disruption of glutamateglutamine-GABA cycle significantly impacts on suicidal behaviour:survey of the literature and own findings on glutamine synthetase. CNS Neurol. Disord. Drug Targets, 2013, 12(7), 900-913. http://dx.doi.org/10.2174/18715273113129990091 PMID:24040807
74. Sokolowski, M.; Ben-Efraim, Y.J.; Wasserman, J.; Wasserman, D. Glutamatergic GRIN2B and polyaminergic ODC1 genes in suicide attempts: associations and gene-environment interactions with childhood/adolescent physical assault. Mol. Psychiatry, 2013, 18(9), 985-992. http://dx.doi.org/10.1038/mp.2012.112 PMID: 22850629
75. Trullas, R.; Skolnick, P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur. J. Pharmacol., 1990, 185(1), 1-10. http://dx.doi.org/10.1016/0014-2999(90)90204-J PMID: 2171955
76. Yilmaz, A.; Schulz, D.; Aksoy, A.; Canbeyli, R. Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol. Biochem. Behav., 2002, 71(1-2), 341-344. http://dx.doi.org/10.1016/S0091-3057(01)00693-1 PMID:11812542
77. Garcia, L.S.; Comim, C.M.; Valvassori, S.S.; Réus, G.Z.; Barbosa, L.M.; Andreazza, A.C.; Stertz, L.; Fries, G.R.; Gavioli, E.C.; Kapczinski, F.; Quevedo, J. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32(1), 140-144. http://dx.doi.org/10.1016/j.pnpbp.2007.07.027 PMID: 17884272
78. Maeng, S.; Zarate, C.A., Jr; Du, J.; Schloesser, R.J.; McCammon, J.; Chen, G.; Manji, H.K. Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-amino-3-hydroxy-5- methylisoxazole-4-propionic acid receptors. Biol. Psychiatry, 2008, 63(4), 349-352. http://dx.doi.org/10.1016/j.biopsych.2007.05.028 PMID: 17643398
79. Wang, N.; Yu, H-Y.; Shen, X-F.; Gao, Z-Q.; Yang, C.; Yang, J-J.; Zhang, G-F. The rapid antidepressant effect of ketamine in rats is associated with down-regulation of pro-inflammatory cytokines in the hippocampus. Ups. J. Med. Sci., 2015, 120(4), 241-248. http://dx.doi.org/10.3109/03009734.2015.1060281 PMID:26220286
80. Réus, G.Z.; Carlessi, A.S.; Titus, S.E.; Abelaira, H.M.; Ignácio, Z.M.; da Luz, J.R.; Matias, B.I.; Bruchchen, L.; Florentino, D.; Vieira, A.; Petronilho, F.; Quevedo, J. A single dose of S-ketamine induces long-term antidepressant effects and decreases oxidative stress in adulthood rats following maternal deprivation. Dev. Neurobiol., 2015, 75(11), 1268-1281. http://dx.doi.org/10.1002/dneu.22283 PMID: 25728399
81. Fuchikami, M.; Thomas, A.; Liu, R.; Wohleb, E.S.; Land, B.B.; DiLeone, R.J.; Aghajanian, G.K.; Duman, R.S. Optogenetic stimulation of infralimbic PFC reproduces ketamine’s rapid and sustained antidepressant actions. Proc. Natl. Acad. Sci. USA, 2015, 112(26), 8106-8111. http://dx.doi.org/10.1073/pnas.1414728112 PMID: 26056286
82. Gass, N.; Schwarz, A.J.; Sartorius, A.; Schenker, E.; Risterucci, C.; Spedding, M.; Zheng, L.; Meyer-Lindenberg, A.; Weber-Fahr, W. Sub-anesthetic ketamine modulates intrinsic BOLD connectivity within the hippocampal-prefrontal circuit in the rat. Neuropsychopharmacology, 2014, 39(4), 895-906. http://dx.doi.org/10.1038/npp.2013.290 PMID: 24136293
83. Grimm, O.; Gass, N.; Weber-Fahr, W.; Sartorius, A.; Schenker, E.; Spedding, M.; Risterucci, C.; Schweiger, J.I.; Böhringer, A.; Zang, Z.; Tost, H.; Schwarz, A.J.; Meyer-Lindenberg, A. Acute ketamine challenge increases resting state prefrontal-hippocampal connectivity in both humans and rats. Psychopharmacology (Berl.), 2015, 232(21-22), 4231-4241. http://dx.doi.org/10.1007/s00213-015-4022-y PMID: 26184011
84. Hay, N.; Sonenberg, N. Upstream and downstream of mTOR. Genes Dev., 2004, 18(16), 1926-1945. http://dx.doi.org/10.1101/gad.1212704 PMID: 15314020
85. Inoki, K.; Ouyang, H.; Zhu, T.; Lindvall, C.; Wang, Y.; Zhang, X.; Yang, Q.; Bennett, C.; Harada, Y.; Stankunas, K.; Wang, C.Y.; He, X.; MacDougald, O.A.; You, M.; Williams, B.O.; Guan, K-L. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell, 2006, 126(5), 955-968. http://dx.doi.org/10.1016/j.cell.2006.06.055 PMID: 16959574
86. Niculescu, A.B.; Levey, D.F.; Phalen, P.L.; Le-Niculescu, H.; Dainton, H.D.; Jain, N.; Belanger, E.; James, A.; George, S.; Weber, H.; Graham, D.L.; Schweitzer, R.; Ladd, T.B.; Learman, R.; Niculescu, E.M.; Vanipenta, N.P.; Khan, F.N.; Mullen, J.; Shankar, G.; Cook, S.; Humbert, C.; Ballew, A.; Yard, M.; Gelbart, T.; Shekhar, A.; Schork, N.J.; Kurian, S.M.; Sandusky, G.E.; Salomon, D.R. Understanding and predicting suicidality using a combined genomic and clinical risk assessment approach. Mol. Psychiatry, 2015, 20(11), 1266-1285. http://dx.doi.org/10.1038/mp.2015.112 PMID: 26283638
87. Flory, J.D.; Donohue, D.; Muhie, S.; Yang, R.; Miller, S.A.; Hammamieh, R.; Ryberg, K.; Yehuda, R. Gene expression associated with suicide attempts in US veterans. Transl. Psychiatry, 2017, 7(9), e1226. http://dx.doi.org/10.1038/tp.2017.179 PMID: 28872639
88. Li, N.; Lee, B.; Liu, R-J.; Banasr, M.; Dwyer, J.M.; Iwata, M.; Li, X-Y.; Aghajanian, G.; Duman, R.S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science, 2010, 329(5994), 959-964. http://dx.doi.org/10.1126/science.1190287 PMID: 20724638
89. Miller, O.H.; Yang, L.; Wang, C-C.; Hargroder, E.A.; Zhang, Y.; Delpire, E.; Hall, B.J. GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. eLife, 2014, 3e03581 http://dx.doi.org/10.7554/eLife.03581 PMID: 25340958
90. Beurel, E.; Song, L.; Jope, R.S. Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol. Psychiatry, 2011, 16(11), 1068-1070. http://dx.doi.org/10.1038/mp.2011.47 PMID: 21502951
91. Liu, R-J.; Fuchikami, M.; Dwyer, J.M.; Lepack, A.E.; Duman, R.S.; Aghajanian, G.K. GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology, 2013, 38(11), 2268-2277. http://dx.doi.org/10.1038/npp.2013.128 PMID: 23680942
92. Chiu, C-T.; Scheuing, L.; Liu, G.; Liao, H-M.; Linares, G.R.; Lin, D.; Chuang, D-M. The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress. Int. J. Neuropsychopharmacol., 2014, 18(6), 18. PMID: 25548109
93. Lepack, A.E.; Fuchikami, M.; Dwyer, J.M.; Banasr, M.; Duman, R.S. BDNF release is required for the behavioral actions of ketamine. Int. J. Neuropsychopharmacol., 2014, 18(1), pyu033- pyu033. http://dx.doi.org/10.1093/ijnp/pyu033 PMID: 25539510
94. Tomasetti, C.; Iasevoli, F.; Buonaguro, E.F.; De Berardis, D.; Fornaro, M.; Fiengo, A.L.; Martinotti, G.; Orsolini, L.; Valchera, A.; Di Giannantonio, M.; de Bartolomeis, A. Treating the synapse in major psychiatric disorders: the role of postsynaptic density network in dopamine-glutamate interplay and psychopharmacologic drugs molecular actions. Int. J. Mol. Sci., 2017, 18(1)E135 http://dx.doi.org/10.3390/ijms18010135 PMID: 28085108
95. Liu, R-J.; Lee, F.S.; Li, X-Y.; Bambico, F.; Duman, R.S.; Aghajanian, G.K. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol. Psychiatry, 2012, 71(11), 996-1005. http://dx.doi.org/10.1016/j.biopsych.2011.09.030 PMID: 22036038
96. Petryshen, T.L.; Sabeti, P.C.; Aldinger, K.A.; Fry, B.; Fan, J.B.; Schaffner, S.F.; Waggoner, S.G.; Tahl, A.R.; Sklar, P. Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. Mol. Psychiatry, 2010, 15(8), 810-815. http://dx.doi.org/10.1038/mp.2009.24 PMID: 19255578
97. Diagnostic and Statistical Manual of Mental Disorders (DSM-5), 5th ed; American Psychiatric Association: Washington, 2013.
98. A study to evaluate the effects of a single-dose and repeatadministration of intranasal esketamine on on-road driving in participants with major depressive disorder: NCT0291957, 9., https://clinicaltrials.gov/ct2/show/NCT02919579.
99. Singh, J.B.; Fedgchin, M.; Daly, E.; Xi, L.; Melman, C.; De Bruecker, G.; Tadic, A.; Sienaert, P.; Wiegand, F.; Manji, H.; Drevets, W.C.; Van Nueten, L. Intravenous esketamine in adult treatment-resistant depression: a double-blind, doublerandomization, placebo-controlled study. Biol. Psychiatry, 2016, 80(6), 424-431. http://dx.doi.org/10.1016/j.biopsych.2015.10.018 PMID: 26707087
100. Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text revision (DSM-IV-TR); American Psychiatric Association:Washington, DC, 2000.
101. Sheehan, D.V.; Lecrubier, Y.; Sheehan, K.H.; Amorim, P.; Janavs., J.; Weiller, E.; Hergueta, T.; Baker, R.; Dunbar, G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry, 1998, 59(Suppl. 20), 22-33. PMID: 9881538
102. Chandler, G.M.; Iosifescu, D.V.; Pollack, M.H.; Targum, S.D.; Fava, M. RESEARCH: validation of the massachusetts general hospital antidepressant treatment history questionnaire (ATRQ). CNS Neurosci. Ther., 2010, 16(5), 322-325. http://dx.doi.org/10.1111/j.1755-5949.2009.00102.x PMID:19769599
103. Trivedi, M.H.; Rush, A.J.; Ibrahim, H.M.; Carmody, T.J.; Biggs, M.M.; Suppes, T.; Crismon, M.L.; Shores-Wilson, K.; Toprac, M.G.; Dennehy, E.B.; Witte, B.; Kashner, T.M. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol. Med., 2004, 34(1), 73-82. http://dx.doi.org/10.1017/S0033291703001107 PMID: 14971628
104. Montgomery, S.A.; Asberg, M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry, 1979, 134, 382-389. http://dx.doi.org/10.1192/bjp.134.4.382 PMID: 444788
105. Alphs, L.; Canuso, C.; Williamson, D. Evaluating changes in factors associated with suicidal thinking using the suicide ideation and behavior assessment tool (SIBAT). Neuropsychopharmacology, 2016, 41(Suppl. 1S), S189.
106. Bremner, J.D.; Krystal, J.H.; Putnam, F.W.; Southwick, S.M.; Marmar, C.; Charney, D.S.; Mazure, C.M. Measurement of dissociative states with the clinician-administered dissociative states scale (CADSS). J. Trauma. Stress, 1998, 11(1), 125-136. http://dx.doi.org/10.1023/A:1024465317902 PMID: 9479681
107. Daly, E.J.; Singh, J.B.; Fedgchin, M.; Cooper, K.; Lim, P.; Shelton, R.C.; Thase, M.E.; Winokur, A.; Van Nueten, L.; Manji, H.; Drevets, W.C. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry, 2018, 75(2), 139-148. http://dx.doi.org/10.1001/jamapsychiatry.2017.3739 PMID:29282469
108. Guy, W.M. ECDEU assessment manual for psychopharmacology; US department of health, education, and welfare: Rockville, MD, 1976.
109. Spitzer, R.L.; Kroenke, K.; Williams, J.B.; Löwe, B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch. Intern. Med., 2006, 166(10), 1092-1097. http://dx.doi.org/10.1001/archinte.166.10.1092 PMID: 16717171
110. Fedgchin, M.; Trivedi, M.; Daly, E.J.; Melkote, R.; Lane, R.; Lim, P.; Vitagliano, D.; Blier, P.; Fava, M.; Liebowitz, M.; Ravindran, A.; Gaillard, R.; Ameele, H.V.D.; Preskorn, S.; Manji, H.; Hough, D.; Drevets, W.C.; Singh, J.B. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, doubleblind, active-controlled study (TRANSFORM-1). Int. J. Neuropsychopharmacol., 2019, 22(10), 616-630. http://dx.doi.org/10.1093/ijnp/pyz039 PMID: 31290965
111. Leon, A.C.; Olfson, M.; Portera, L.; Farber, L.; Sheehan, D.V. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int. J. Psychiatry Med., 1997, 27(2), 93-105. http://dx.doi.org/10.2190/T8EM-C8YH-373N-1UWD PMID:9565717
112. Spitzer, R.L.; Kroenke, K.; Williams, J.B. Validation and utility of a self-report version of prime-MD: the PHQ primary care study. primary care evaluation of mental disorders. patient health questionnaire. JAMA, 1999, 282(18), 1737-1744. http://dx.doi.org/10.1001/jama.282.18.1737 PMID: 10568646
113. About EQ-5D., http://www.euroqol.org/about-eq-5d.html
114. Overall, J.E.; Gorham, D.R. The brief psychiatric rating scale. Psychol. Rep., 1962, 10, 799-812. http://dx.doi.org/10.2466/pr0.1962.10.3.799
115. Rickels, K.; Garcia-Espana, F.; Mandos, L.A.; Case, G.W. Physician Withdrawal Checklist (PWC-20). J. Clin. Psychopharmacol., 2008, 28(4), 447-451. http://dx.doi.org/10.1097/JCP.0b013e31817efbac PMID: 18626273
116. Popova, V.; Daly, E.J.; Trivedi, M.; Cooper, K.; Lane, R.; Lim, P.; Mazzucco, C.; Hough, D.; Thase, M.E.; Shelton, R.C.; Molero, P.; Vieta, E.; Bajbouj, M.; Manji, H.; Drevets, W.C.; Singh, J.B. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatmentresistant depression: a randomized double-blind active-controlled study. Am. J. Psychiatry, 2019, 176(6), 428-438. http://dx.doi.org/10.1176/appi.ajp.2019.19020172 PMID: 31109201
117. Ochs-Ross, R.; Daly, E.J.; Zhang, Y.; Lane, R.; Lim, P.; Foster, K.; Hough, D.; Manji, H.; Drevets, W.C.; Sanacora, G.; Adler, C.; McShane, R.; Gaillard, R.; Singh, J.B. S114. Efficacy and safety of intranasal esketamine plus an oral antidepressant in elderly patients with treatment-resistant depression. Biol. Psychiatry, 2018, 83, S391. http://dx.doi.org/10.1016/j.biopsych.2018.02.1005
118. Wajs, E.; Leah, A.; Morrison, R. Long-term safety of esketamine nasal spray plus oral antidepressant in patients with treatmentresistant depression: SUSTAIN-2 phase study. Eur. Neuropsychopharmacol., 2019, 29, S44-S45. http://dx.doi.org/10.1016/j.euroneuro.2018.11.1016
119. Daly, E.J.; Trivedi, M.H.; Janik, A.; Li, H.; Zhang, Y.; Li, X.; Lane, R.; Lim, P.; Duca, A.R.; Hough, D.; Thase, M.E.; Zajecka, J.; Winokur, A.; Divacka, I.; Fagiolini, A.; Cubala, W.J.; Bitter, I.; Blier, P.; Shelton, R.C.; Molero, P.; Manji, H.; Drevets, W.C.; Singh, J.B. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry, 2019. [Epub ahead of print] http://dx.doi.org/10.1001/jamapsychiatry.2019.1189 PMID:31166571
120. A study to evaluate the efficacy and safety of intranasal esketamine in addition to comprehensive standard of care for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in adult participants assessed to be at imminent risk for suicide (aspire i). 54135419SUI3001. https://clinicaltrials.gov/ct2/show/nct03039192
121. A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide (Aspire II). 54135419SUI3002. https://clinicaltrials.gov/ct2/show/nct03097133
122. Ajub, E.; Lacerda, A.L.T. Efficacy of Esketamine in the Treatment of Depression With Psychotic Features: A Case Series. Biol. Psychiatry, 2018, 83(1), e15-e16. http://dx.doi.org/10.1016/j.biopsych.2017.06.011 PMID: 28728676
123. Correia-Melo, F.S.; Argolo, F.C.; Araújo-de-Freitas, L.; Leal, G.C.; Kapczinski, F.; Lacerda, A.L.; Quarantini, L.C. Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review. Neuropsychiatr. Dis. Treat., 2017, 13, 1627-1632. http://dx.doi.org/10.2147/NDT.S135623 PMID: 28790825
124. Correia-Melo, F.S.; Leal, G.C.; Carvalho, M.S.; Jesus-Nunes, A.P.; Ferreira, C.B.N.; Vieira, F.; Magnavita, G.; Vale, L.A.S.; Mello, R.P.; Nakahira, C.; Argolo, F.C.; Cardoso, T.; Souza, C.D.S.; Fontes, A.T.C.; Ferreira, M.B.; Araújo-de-Freitas, L.; Tuena, M.A.; Echegaray, M.V.F.; Cavalcanti, D.E.; Lucchese, A.C.; Bandeira, I.D.; Telles, M.; Lima, C.S.; Sampaio, A.S.; Silva, S.S.; Marback, R.F.; Del-Porto, J.A.; Abreu, J.N.; Sarin, L.M.; Paixão, C.S.; Carvalho, L.P.; Machado, P.R.L.; Turecki, G.; Lacerda, A.L.T.; Quarantini, L.C. Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a noninferiority clinical trial. Medicine (Baltimore), 2018, 97(38), e12414. http://dx.doi.org/10.1097/MD.0000000000012414 PMID:30235716
125. Targum, S.D.; Daly, E.; Fedgchin, M.; Cooper, K.; Singh, J.B. Comparability of blinded remote and site-based assessments of response to adjunctive esketamine or placebo nasal spray in patients with treatment resistant depression. J. Psychiatr. Res., 2019, 111, 68-73. http://dx.doi.org/10.1016/j.jpsychires.2019.01.017 PMID:30685564
126. Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in treatment-resistant Depression: NCT03965858., https://clinicaltrials.gov/ct2/show/NCT03965858
127. Study to evaluate the efficacy and safety of 3 fixed doses of intranasal esketamine in addition to comprehensive standard of care for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in pediatric participants assessed to be at imminent risk for suicide: NCT03185819. https://clinicaltrials.gov/ct2/show/NCT03185819
128. A study to evaluate the efficacy, safety and tolerability of fixed doses of intranasal esketamine in Japanese participants with treatment resistant depression: NCT02918318. https://clinicaltrials.gov/ct2/show/NCT02918318.
129. A study to evaluate the efficacy, pharmacokinetics, safety and tolerability of flexible doses of intranasal esketamine plus an oral antidepressant in adult participants with treatment-resistant depression. NCT03434041, https://clinicaltrials.gov/ct2/show/NCT03434041
130. A long-term safety study of esketamine nasal spray in treatmentresistant depression: NCT02782104., https://clinicaltrials.gov/ct2/show/NCT02782104
131. A study of esketamine nasal spray plus a new standard-of-care oral antidepressant or placebo nasal spray plus a new standard-of-care oral antidepressant in adult and elderly participants with treatmentresistant depression: nct03852160., https://clinicaltrials.gov/ct2/show/NCT03852160
132. Reiner, A.; Levitz, J. Glutamatergic signaling in the central nervous system: ionotropic and metabotropic receptors in concert. Neuron, 2018, 98(6), 1080-1098. http://dx.doi.org/10.1016/j.neuron.2018.05.018 PMID: 29953871
133. Ulbrich, M.H.; Isacoff, E.Y. Rules of engagement for NMDA receptor subunits. Proc. Natl. Acad. Sci. USA, 2008, 105(37), 14163-14168. http://dx.doi.org/10.1073/pnas.0802075105 PMID: 18779583
134. Peyrovian, B.; Rosenblat, J.D.; Pan, Z.; Iacobucci, M.; Brietzke, E.; McIntyre, R.S. The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2019, 92, 387-404. http://dx.doi.org/10.1016/j.pnpbp.2019.02.001 PMID: 30738126
135. Zarate, C.A., Jr; Singh, J.B.; Carlson, P.J.; Brutsche, N.E.; Ameli, R.; Luckenbaugh, D.A.; Charney, D.S.; Manji, H.K. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry, 2006, 63(8), 856-864. http://dx.doi.org/10.1001/archpsyc.63.8.856 PMID: 16894061
136. Mathew, S.J.; Shah, A.; Lapidus, K.; Clark, C.; Jarun, N.; Ostermeyer, B.; Murrough, J.W. Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs, 2012, 26(3), 189-204. http://dx.doi.org/10.2165/11599770-000000000-00000 PMID:22303887
137. Phillips, M.L.; Drevets, W.C.; Rauch, S.L.; Lane, R. Neurobiology of emotion perception II: Implications for major psychiatric disorders. Biol. Psychiatry, 2003, 54(5), 515-528. http://dx.doi.org/10.1016/S0006-3223(03)00171-9 PMID:12946880
138. Ibrahim, L.; Diazgranados, N.; Franco-Chaves, J.; Brutsche, N.; Henter, I.D.; Kronstein, P.; Moaddel, R.; Wainer, I.; Luckenbaugh, D.A.; Manji, H.K.; Zarate, C.A., Jr. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs. add-on riluzole: results from a 4-week, double-blind, placebocontrolled study. Neuropsychopharmacology, 2012, 37(6), 1526-1533. http://dx.doi.org/10.1038/npp.2011.338 PMID: 22298121
139. Yang, C.; Shirayama, Y.; Zhang, J.C.; Ren, Q.; Yao, W.; Ma, M.; Dong, C.; Hashimoto, K. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl. Psychiatry, 2015, 5e632 http://dx.doi.org/10.1038/tp.2015.136 PMID: 26327690
140. Hashimoto, K.; Kakiuchi, T.; Ohba, H.; Nishiyama, S.; Tsukada, H. Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys. Eur. Arch. Psychiatry Clin. Neurosci., 2017, 267(2), 173-176. http://dx.doi.org/10.1007/s00406-016-0692-7 PMID: 27091456
141. Drevets, W.C.; Singh, J.B.; Hough, D.; Daly, E.J.; Popova, V.; Manji, H. Comment on a word to the wise about intranasal esketamine. Am. J. Psychiatry, 2019, 176(10), 856-857. http://dx.doi.org/10.1176/appi.ajp.2019.19070688 PMID: 31569984